Turval
  • Contact
  • Press And News

Womens Health

 

Candida albicans, significant decrease.

Trial 129: Verification of the decrease of Candida albicans in the gastrointestinal tract of healthy subjects, after supplementation of the lactic yeast Kluyveromyces marxianus fragilis B0399, through

Candida albicans: Kluyveromyces B0399 direct inhibitory activity

Trial 96: In vitro test on the effect of the typified lactic yeast (Kluyveromyces marxianus B0399) on the development of Candida albicans ATCC10231. Authors: Dr. Tiziana Cettolo, Dr. Lorena Riul &nd

Probiotic Lactic Yeast ® Kluyveromyces B0399: immune system stimulation, gut colonization, bifidobogenic effect and other strain specific, probiotic properties

Trial 143: Potential probiotic Kluyveromyces marxianus fragilis B0399 modulates the immune response in Caco-2 cells and PBMCs and impacts on the human gut microbiota in an in vitro colonic model syste
2025. © All rights reserved. Laboratori Turval Italia srl (TURVAL Laboratories Ltd.) - Head Office and Research Dpt: Friuli innovazione (AREA international Science Park-TS), Via Linussio 51-33100 Udine (IT) – P. IVA 01883020305

TURVAL

WE VALUE YOUR PRIVACY

We use cookies to enhance your browsing experience and analyse our traffic. By clicking Accept All, you consent to our use of cookies. Cookie Policy